Journal
HEMATOLOGY REPORTS
Volume 7, Issue 1, Pages 12-14Publisher
PAGEPRESS PUBL
DOI: 10.4081/hr.2015.5704
Keywords
multiple myeloma; central neurotoxicity; immunomodulatory drugs; thalidomide; lenalidomide; pomalidomide
Categories
Ask authors/readers for more resources
Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available